Press Release

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.3%1-day move

₹531.75

prior close

₹531.70

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.9-2.3-2.5-1.4-3.3-2.2-3.6-1.6-2.1+0.1+2.1+16.4+30.2—

Up moveDown movePending

AI summary

Akums Drugs reported Q4 FY26 operating revenue of ₹1,158 crore, up 9.7% YoY, with Adj EBITDA of ₹152 crore (up 61.6% YoY) and Adj PAT of ₹83 crore (up 135% YoY). Full-year FY26 revenue stood at ₹4,359 crore (5.9% growth), with Adj EBITDA at ₹522 crore (13.3% growth) and Adj PAT at ₹276 crore (27.3% growth). EBITDA margin improved to 13.1% in Q4 from 8.9% YoY. The CDMO segment was the key growth driver with revenue of ₹952 crore and 54.9% EBITDA growth. The API business continued to face pricing pressure with operating loss of ₹12 crore in Q4. Board recommended dividend of ₹1 per share plus special dividend of ₹2 per share.

Likely market impact

Strong profitability improvement with PAT growth of 27.3% and EBITDA margin expansion signals operational efficiency gains. The special dividend and CDMO business momentum are positive signals for investors, though slow API turnaround remains a concern.